UCB Achieves Important Regulatory Milestone for Bimekizumab
Go back to UCB Achieves Important Regulatory Milestone for Bimekizumab| (NYSE: UCB) | Delayed: 35.52 -0.01 (0.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $35.53 | 52 Week High | $ | |||
| Open | $35.83 | 52 Week Low | $ | |||
| Day High | $35.91 | P/E | N/A | |||
| Day Low | $35.28 | EPS | $ | |||
| Volume | 194,335 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 129.29 +3.18 (2.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.11 | 52 Week High | $46.25 | |||
| Open | $127.28 | 52 Week Low | $32.74 | |||
| Day High | $129.41 | P/E | N/A | |||
| Day Low | $127.28 | EPS | $0.00 | |||
| Volume | 24,360 | |||||
